The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages

PLoS One. 2014 Apr 15;9(4):e94188. doi: 10.1371/journal.pone.0094188. eCollection 2014.

Abstract

Macrophages are important innate immune cells that are associated with two distinct phenotypes: a pro-inflammatory (or classically activated) subset with prototypic macrophage functions such as inflammatory cytokine production and bactericidal activity, and an anti-inflammatory (or alternatively activated (AAM)) subset linked with wound healing and tissue repair processes. In this study, we examined the effect of interlukein-6 on human and murine macrophage polarization. The results indicate that despite being commonly associated with pro-inflammatory functions and being implicated in the pathogenesis/pathophysiology of numerous inflammatory diseases, interleukin-6 can enhance the polarization of AAMs, based on increased expression of hallmark markers: arginase-1, Ym1 and CD206; this effect required the AAM differentiating cytokines, IL-4 and IL-13. Co-treatment of AAMs with IL-6 resulted in spontaneous release of IL-10, suppressed LPS-induced nitric oxide production and inhibited cytokine production by activated CD4+ T cells - immunoregulatory features not observed in the 'parent' IL-4+IL-13-induced AAM. The effect of IL-6 required signal transducer and activator of transcription (STAT)-3, was partially dependent on up-regulation of the IL4Rα chain, and was independent of autocrine IL-10. In the presence of IFNγ, IL-6 promoted the production of IL-1β and TNFα suggesting that this cytokine can enhance the phenotype to which a macrophage has committed. This finding may explain the pleiotrophic nature of IL-6, where it is associated with the perpetuation and enhancement of disease in inflammatory situations, but is also necessary for resolution of inflammation and adequate wound healing to occur in others. Thus, the potential benefit of IL-6 in promoting an AAM, with its' anti-inflammatory and wound healing ability, may need to be considered in immunotherapies aimed at in vivo modulation or inhibition of IL-6.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chemokines / metabolism
  • Humans
  • Inflammation / metabolism
  • Interleukin-13 / pharmacology
  • Interleukin-4 / pharmacology
  • Interleukin-6 / pharmacology*
  • Macrophage Activation / drug effects*
  • Macrophages / cytology
  • Macrophages / drug effects*
  • Macrophages / immunology*
  • Macrophages / metabolism
  • Male
  • Mice
  • Monocytes / cytology
  • Monocytes / drug effects
  • Monocytes / immunology
  • Monocytes / metabolism
  • Phenotype
  • Receptors, Cell Surface / metabolism
  • Recombinant Proteins / pharmacology
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / metabolism
  • Up-Regulation / drug effects

Substances

  • Chemokines
  • Il4ra protein, mouse
  • Interleukin-13
  • Interleukin-6
  • Receptors, Cell Surface
  • Recombinant Proteins
  • STAT3 Transcription Factor
  • Interleukin-4